Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.

Ito Y, Sadar MD.

Res Rep Urol. 2018 Feb 16;10:23-32. doi: 10.2147/RRU.S157116. eCollection 2018. Review.

2.

Order within a Disordered Structure.

Tien AH, Sadar MD.

Structure. 2018 Jan 2;26(1):4-6. doi: 10.1016/j.str.2017.12.007.

PMID:
29298412
3.

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.

Myung JK, Wang G, Chiu HH, Wang J, Mawji NR, Sadar MD.

PLoS One. 2017 Mar 17;12(3):e0174134. doi: 10.1371/journal.pone.0174134. eCollection 2017.

4.

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer.

Leung JK, Sadar MD.

Front Endocrinol (Lausanne). 2017 Jan 17;8:2. doi: 10.3389/fendo.2017.00002. eCollection 2017. Review.

5.

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Antonarakis ES, Chandhasin C, Osbourne E, Luo J, Sadar MD, Perabo F.

Oncologist. 2016 Dec;21(12):1427-1435. Epub 2016 Sep 14.

6.

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.

Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L, Wen JG, Andersen RJ, Sadar MD.

J Biol Chem. 2016 Oct 14;291(42):22231-22243. Epub 2016 Aug 30.

7.

An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.

Imamura Y, Tien AH, Pan J, Leung JK, Banuelos CA, Jian K, Wang J, Mawji NR, Fernandez JG, Lin KS, Andersen RJ, Sadar MD.

JCI Insight. 2016 Jul 21;1(11). pii: e87850.

8.

Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.

Imamura Y, Sadar MD.

Int J Urol. 2016 Aug;23(8):654-65. doi: 10.1111/iju.13137. Epub 2016 Jun 14. Review.

9.

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD.

Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2.

10.

Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.

Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD.

Clin Cancer Res. 2016 Jun 1;22(11):2744-54. doi: 10.1158/1078-0432.CCR-15-2119. Epub 2015 Dec 28.

11.

N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Martin SK, Banuelos CA, Sadar MD, Kyprianou N.

Mol Oncol. 2014 Nov 15. pii: S1574-7891(14)00263-4. doi: 10.1016/j.molonc.2014.10.014. [Epub ahead of print]

12.

Characterization of niphatenones that inhibit androgen receptor N-terminal domain.

Banuelos CA, Lal A, Tien AH, Shah N, Yang YC, Mawji NR, Meimetis LG, Park J, Kunzhong J, Andersen RJ, Sadar MD.

PLoS One. 2014 Sep 30;9(9):e107991. doi: 10.1371/journal.pone.0107991. eCollection 2014.

13.

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD.

J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3.

14.

Spongian diterpenoids inhibit androgen receptor activity.

Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD.

Mol Cancer Ther. 2013 May;12(5):621-31. doi: 10.1158/1535-7163.MCT-12-0978. Epub 2013 Feb 26.

15.

Large scale phosphoproteome analysis of LNCaP human prostate cancer cells.

Myung JK, Sadar MD.

Mol Biosyst. 2012 Aug;8(8):2174-82. doi: 10.1039/c2mb25151e. Epub 2012 Jun 14.

16.

Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity.

Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ.

J Med Chem. 2012 Jan 12;55(1):503-14. doi: 10.1021/jm2014056. Epub 2011 Dec 28.

PMID:
22148427
17.

FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.

Haile S, Lal A, Myung JK, Sadar MD.

PLoS One. 2011;6(9):e24197. doi: 10.1371/journal.pone.0024197. Epub 2011 Sep 1.

18.

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.

Sadar MD.

World J Urol. 2012 Jun;30(3):311-8. doi: 10.1007/s00345-011-0745-5. Epub 2011 Aug 11. Review.

PMID:
21833557
19.

Androgen receptor and its splice variants in prostate cancer.

Haile S, Sadar MD.

Cell Mol Life Sci. 2011 Dec;68(24):3971-81. doi: 10.1007/s00018-011-0766-7. Epub 2011 Jul 12. Review.

20.

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

Sadar MD.

Cancer Res. 2011 Feb 15;71(4):1208-13. doi: 10.1158/0008-5472.CAN_10-3398. Epub 2011 Feb 1. Review.

21.

LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD.

BMC Med Genomics. 2010 Sep 24;3:43. doi: 10.1186/1755-8794-3-43.

22.

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor.

Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y.

Prostate. 2010 Nov 1;70(15):1636-44. doi: 10.1002/pros.21199.

PMID:
20564316
23.

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, BaƱuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD.

Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027.

24.

Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.

Chiu HH, Yong TM, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD.

Cancer Lett. 2010 Jun 28;292(2):176-85. doi: 10.1016/j.canlet.2009.11.023. Epub 2009 Dec 30.

25.

Novel biomarkers for prostate cancer including noncoding transcripts.

Romanuik TL, Ueda T, Le N, Haile S, Yong TM, Thomson T, Vessella RL, Sadar MD.

Am J Pathol. 2009 Dec;175(6):2264-76. doi: 10.2353/ajpath.2009.080868. Epub 2009 Nov 5.

26.

Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries.

Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, Sadar MD.

BMC Genomics. 2009 Oct 15;10:476. doi: 10.1186/1471-2164-10-476.

27.

Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.

Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF, Lam S.

J Clin Oncol. 2009 Jun 10;27(17):2787-92. doi: 10.1200/JCO.2008.19.4233. Epub 2009 May 4.

28.

Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA, Sadar MD.

Cancer Res. 2009 Apr 15;69(8):3433-42. doi: 10.1158/0008-5472.CAN-08-3506. Epub 2009 Apr 7.

29.

Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Wang G, Wang J, Sadar MD.

Cancer Res. 2008 Dec 1;68(23):9918-27. doi: 10.1158/0008-5472.CAN-08-1718.

30.

Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.

Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV, Andersen RJ.

Org Lett. 2008 Nov 6;10(21):4947-50. doi: 10.1021/ol802021w. Epub 2008 Oct 4.

PMID:
18834139
31.

ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.

Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ.

Cancer Res. 2008 Jun 1;68(11):4352-9. doi: 10.1158/0008-5472.CAN-07-5237.

32.

14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens.

Quayle SN, Sadar MD.

Cancer Lett. 2007 Aug 28;254(1):137-45. Epub 2007 Apr 12.

33.

Novel expressed sequences identified in a model of androgen independent prostate cancer.

Quayle SN, Hare H, Delaney AD, Hirst M, Hwang D, Schein JE, Jones SJ, Marra MA, Sadar MD.

BMC Genomics. 2007 Jan 26;8:32.

34.

Androgen receptor decoy molecules block the growth of prostate cancer.

Quayle SN, Mawji NR, Wang J, Sadar MD.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1331-6. Epub 2007 Jan 16.

35.
36.

Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach.

Bainbridge MN, Warren RL, Hirst M, Romanuik T, Zeng T, Go A, Delaney A, Griffith M, Hickenbotham M, Magrini V, Mardis ER, Sadar MD, Siddiqui AS, Marra MA, Jones SJ.

BMC Genomics. 2006 Sep 29;7:246.

37.

Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells.

Wang G, Jones SJ, Marra MA, Sadar MD.

Oncogene. 2006 Nov 23;25(55):7311-23. Epub 2006 Jun 5.

PMID:
16751804
38.

Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells.

Sobel RE, Wang Y, Sadar MD.

In Vitro Cell Dev Biol Anim. 2006 Jan-Feb;42(1-2):33-9.

PMID:
16618209
39.
40.

A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells.

Quayle SN, Sadar MD.

Genomics. 2006 May;87(5):633-7. Epub 2006 Jan 24.

41.

Interleukin-4 in patients with prostate cancer.

Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T.

Anticancer Res. 2005 Nov-Dec;25(6C):4595-8.

42.

An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line.

Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ.

Lab Invest. 2005 Nov;85(11):1392-404.

43.

Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.

Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD.

Clin Chem. 2005 Apr;51(4):695-707. Epub 2005 Feb 3.

44.

Cell lines used in prostate cancer research: a compendium of old and new lines--part 2.

Sobel RE, Sadar MD.

J Urol. 2005 Feb;173(2):360-72. Review.

PMID:
15643173
45.

Cell lines used in prostate cancer research: a compendium of old and new lines--part 1.

Sobel RE, Sadar MD.

J Urol. 2005 Feb;173(2):342-59. Review.

PMID:
15643172
46.
47.

Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells.

Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD.

Clin Cancer Res. 2004 Mar 1;10(5):1860-9.

48.

Androgens and androgen receptor in prostate and ovarian malignancies.

Meehan KL, Sadar MD.

Front Biosci. 2003 May 1;8:d780-800. Review.

PMID:
12700055
49.
50.

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells.

Ueda T, Mawji NR, Bruchovsky N, Sadar MD.

J Biol Chem. 2002 Oct 11;277(41):38087-94. Epub 2002 Aug 5.

Supplemental Content

Loading ...
Support Center